Chesapeake Bay health grade dips after hottest year on record and extreme rainfall patterns
ANNAPOLIS, Md. (AP) — The health of the Chesapeake Bay declined in an annual report card on the nation's largest estuary released Tuesday, with scientists noting the effect of extreme rainfall patterns during the hottest year on record.
The University of Maryland Center for Environmental Science gave the bay a C grade in its report card. That compares to a C-plus grade the bay received last year, which was the highest grade it had received since 2002.
'There was a substantial upturn in the overall Bay Health score in 2024, and it came down a little this year,' said Heath Kelsey, director of UMCES Integration and Application Network. 'Over the long term, though, there is still an improving trend from the 1980s until now. We think extreme weather may have had some impact on the scores this year.'
The report noted that last year was the hottest year on record, with extreme rainfall patterns.
'While parts of the watershed experienced drought, brief but intense downpours can cause water to flow over the ground rather than soak into it, increasing the fertilizer, dirt, and debris carried into waterways,' the report said.
Bill Dennison, vice president for Science Application at UMCES, said the changing climate is definitely having an effect on the bay.
'One of the things that we saw in Maryland, in particular, was a prolonged summer drought — not so much spring, but a summer drought — punctuated by these extreme runoff events,' Dennison said. 'So what was happening was that the crops didn't have enough water, so they're not soaking up the nutrients.'
As a result, when it did rain, there were excess nutrients, like nitrogen and phosphorus, that were flowing into the bay, Dennison said.
'Now sadly, this is kind of our future,' Dennison said at a news conference at the Annapolis Maritime Museum near the bay. 'This is the kind of weather patterns that are starting to become more common, which is drought punctuated by extreme events.'
Warmer weather winters and higher temperatures mean less oxygen in the water for aquatic life, stressing fish and shellfish, Dennison added.
'So these are some of the things that we have to overcome and build more resilience into our system,' Dennison said.
Despite the grade drop, the report cited long-term improvements in dissolved oxygen in the bay's waters. That's the amount of oxygen present in the water that is needed to support bay aquatic life.
The report also noted long-term improvements in aquatic grasses, which provide habitat and food for various species, improve water quality and protect shorelines from erosion.
Phosphorus and nitrogen levels also have improved in the long-term in another positive sign. While they are needed by the bay's organisms, excessive nitrogen and phosphorus degrade the bay's water quality. Excess nitrogen and phosphorus fuel algal blooms that can cloud the water and block sunlight from reaching underwater grasses.
Water clarity and chlorophyll-a scores, however, have declining long-term trends, the report said. Chlorophyll-a in the bay is an indicator of phytoplankton abundance and water quality.
Improving trends can be attributed to management and restoration efforts at the regional, state, and local levels, the report said. Regionally, wastewater treatment plants have been upgraded and programs have been put in place to reduce nutrient and sediment input.
The health of the bay is a reflection of what's happening across its six-state watershed, which includes Delaware, Maryland, New York, Pennsylvania, Virginia and West Virginia along with the District of Columbia.
UMCES, which is marking its 100th anniversary, also provides a grade for the overall watershed health in its report card. It gave the watershed a grade of C-plus. The watershed health grade includes ecological, societal and economic indicators.
The most concerning societal indicator was heat vulnerability, the report said, noting communities may be under heat stress due to hotter air temperatures, less tree canopy cover, and more paved surfaces.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
30 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
30 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
Yahoo
an hour ago
- Yahoo
SpaceX late-night rocket launch in Florida: What time is liftoff, what to know
A late-night rocket launch from Florida is on the horizon. SpaceX is set to launch a batch of Starlink satellites into low-Earth orbit on June 22 from Cape Canaveral. Rockets here launch from NASA's Kennedy Space Center or nearby Cape Canaveral Space Force Station. Weather permitting and depending on cloud cover, a rocket launch from Florida's Space Coast could be visible as far north as Jacksonville Beach and Daytona Beach to as far south as Vero Beach and West Palm Beach. When there's a launch window in the middle of the night or very early morning, there's an opportunity for unique photos — the rocket lights up the dark sky and the contrail after makes for a great photo. Below is more information about the SpaceX rocket launch in Florida and suggestions on where to watch them from here. Rocket launch tally: Here's a list of all 2025 missions from Cape Canaveral, Florida (psst, there's a lot) For questions or comments, email FLORIDA TODAY Space Reporter Rick Neale at rneale@ or Space Reporter Brooke Edwards at bedwards@ For more space news from the USA TODAY Network, visit Tom Cruise and untitled SpaceX project: 'Mission: Impossible' star who lives in Florida may shoot a film in outer space Mission: A SpaceX Falcon 9 rocket will launch a payload of Starlink broadband satellites into low-Earth orbit, a National Geospatial-Intelligence Agency navigational warning shows. Launch window: 1:47 a.m. to 6:17 a.m. ET Sunday, June 22, 2025 Launch location: Launch complex 40 at Cape Canaveral Space Force Station in Cape Canaveral, Florida Trajectory: Northeast Live coverage starts 90 minutes before liftoff at : You can watch live rocket launch coverage from USA TODAY Network's Space Team, which consists of FLORIDA TODAY space reporters Rick Neale and Brooke Edwards and visuals journalists Craig Bailey, Malcolm Denemark and Tim Shortt. Our Space Team will provide up-to-the-minute updates in a mobile-friendly live blog, complete with a countdown clock, at starting 90 minutes before liftoff. You can download the free FLORIDA TODAY app, which is available in the App Store or Google Play, or type into your browser. Shown is the National Weather Service-Melbourne radar, which shows conditions in real-time for the Space Coast, Brevard County, Orlando and other parts of Florida. The current date and time show up on the bottom right of this radar embed; otherwise, you may need to clear your cache. Weather permitting and depending on cloud cover, some rocket launches from the Space Coast can be visible in Palm Beach County. When there's a launch window in the middle of the night or very early morning, with a southeast trajectory, there's an opportunity for unique photos. Some examples include United Launch Alliance's Delta IV Heavy rocket launch and SpaceX Falcon Heavy rocket. From Cape Canaveral, Florida, to West Palm Beach, Florida, it's about 150 miles. What the views look like: Rocket launches from Cape Canaveral spotted in West Palm Beach Rocket launches from Cape Canaveral can often be seen from Palm Beach County, and it can be as easy as walking out of your house and looking north. Try to get away from any obstructions, such as trees, tall buildings, and bright lights. Obviously, cloud cover can also get in the way. If the forecast is for clear skies and you want a better view, some good places to watch the rocket launch from Palm Beach County include: : 14775 U.S. 1, Juno Beach : Downtown West Palm Beach, 620 South Flagler Drive : 300 block of South Ocean Boulevard : If you don't know, this is the island that connects Palm Beach and West Palm Beach on Southern Boulevard (near Mar-a-Lago, Trump's private club known as the Winter White House or Southern White House). There's a bridge with a pedestrian walkway over Bingham Island, on Southern Boulevard. : 10 South Ocean Blvd., Lake Worth Beach : 10216 Lee Road, Boynton Beach : 400 N. State Road A1A, Boca Raton This article originally appeared on Palm Beach Post: SpaceX rocket launch in Florida: When to look up in Palm Beach County
